FindTrial
Sign In

Can a Blood Test Predict Outcomes in Patients with Heart Failure with Normal Pumping Function

To Study Serum Chromogranin A Levels in Heart Failure with Preserved Ejection Fraction as a Prognostic Marker A Longitudinal Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/105224
Enrollment
80
Registered
2026-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I503- Diastolic (congestive) heart failure

Interventions

Intervention1: Nil: Nil

Sponsors

JNMC BELAGAVI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed HFpEF 2D Echo EF 50% or more NTproBNP more than 300 pg/ml Provided informed consent

Exclusion criteria

Exclusion criteria: Chronic Kidney Disease Chronic Liver Disease Neuroendocrine tumors

Design outcomes

Primary

MeasureTime frame
Composite outcome of heart failure related readmission or all-cause mortality within 6 months.Timepoint: Composite outcome of heart failure related readmission or all-cause mortality at 2, 4 and 6 months.—

Secondary

MeasureTime frame
Incremental predictive value of CGA over NT-proBNPTimepoint: at 2, 4 & 6 months—

Countries

India

Contacts

Public ContactVineet Patil

JNMC BELAGAVI

drrekhaspatil@gmail.com9448371125

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026